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confirmed by multivariate analysis (ADMA vs. LVMI,  Left ventricular hypertrophy, cardiac remodeling and asym-
0.17, P  0.006; ADMA vs. EF,   0.24, P  0.001).metric dimethylarginine (ADMA) in hemodialysis patients.
Conclusions. Overall, this study indicates that raised plasmaBackground. The endogenous inhibitor of nitric oxide (NO),
asymmetric dimethylarginine (ADMA), is a strong predictor concentration of ADMA is associated to concentric LVH and
of adverse cardiovascular outcomes in patients with end-stage LV dysfunction. Intervention studies are needed to see whether
renal disease (ESRD). the link between ADMA and concentric LVH remodeling and
Methods. Since arterial and cardiac remodeling is associated LV dysfunction is a causal one.
with altered endothelial microcirculatory responses to forearm
ischemia (a NO-dependent response), interference of ADMA
with the NO system may be important for the pathogenesis of
left ventricular hypertrophy (LVH) in these patients. This study Left ventricular hypertrophy (LVH) is a major risk
sought to identify the relationship between plasma ADMA and
factor for overall and cardiovascular mortality in patientsLV geometry and function in a cohort of 198 hemodialysis
with end-stage renal disease (ESRD) [1]. The pathogen-patients.
Results. Plasma ADMA was significantly higher (P 0.008) esis of LVH in these patients is multifactorial [2] and
in patients with LVH (median 3.00mol/L, inter-quartile range several causative factors have been identified including
1.73 to 3.97 mol/L) than in those without this alteration (1.88 hypertension, anemia, hypoalbuminemia, hyperparathy-mol/L, 1.15 to 3.56 mol/L) and was significantly related to
roidism, chronic volume expansion and, possibly, hyper-left ventricular (LV) mass (r  0.26, P  0.001). Interestingly,
ADMA was much higher (P  0.001) in patients with concen- homocysteinemia [3]. A new potential risk factor for LVH
tric LVH (3.60 mol/L, 2.90 to 4.33 mol/L) than in patients in these patients is the accumulation of the endogenous
with eccentric LVH (2.17 mol/L, 1.47 to 3.24 mol/L) or nor- inhibitor of nitric oxide synthase (NOS), asymmetric di-mal LV mass (1.76 mol/L, 1.13 to 2.65 mol/L). Furthermore,
methylarginine (ADMA). ADMA is related to the se-plasma ADMA was higher (P  0.02) in patients with systolic
dysfunction (3.52 mol/L, 2.08 to 5.87 mol/L) than in those verity of atherosclerosis independently of other vascu-
with normal LV function (2.58 mol/L, 1.53 to 3.84 mol/L) lopathic factors [4]. We have recently found that this
and inversely related to ejection fraction (EF; r  0.25, P  substance is a powerful predictor of overall and cardio-0.001). The link between ADMA and LV mass and EF was
vascular mortality in hemodialysis patients [5].
The interference of ADMA with the nitric oxide (NO)
1 Cardiovascular Risk Extended Evaluation in Dialysis Patients system may be important for the pathogenesis of LVH
(CREED) Investigators also include: Giuseppe Enia, Vincenzo Panuc- because NO modulates the growth of the myocardiumcio, Sebastiano Cutrupi, Carmela Marino, Rocco Tripepi, Vincenzo
[6]. In experimental models inhibition of NOS generatesCandela, Graziella Bonanno, Giuseppe Seminara, Giuseppe Giacone,
Emilio Cottini, Onofrio Marzolla, Carlo Labate, and Filippo Tassone. a NO-deficient hypertension that is associated with the
development of concentric LVH [7]. Of note, arterial andKey words: ADMA, dialysis, uremia, cardiovascular, risk, LVH, sys-
tolic dysfunction, nitric oxide. cardiac remodeling in ESRD have recently been associ-
ated with altered endothelial microcirculatory responses
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Table 1. Somatometric, clinical and biochemical data oftion of ADMA, left ventricular (LV) mass, LV geometry
the study population
and function in a large group of patients with ESRD.
Somatometric data
Age years 58.815.0
BMI kg/m2 24.54.4METHODS Cardiovascular risk factors
Systolic pressure mm Hg 131.823.3Protocol
Diastolic pressure mm Hg 73.912.3
Diabetics 14%The protocol was in conformity to the ethical guide-
Smokers 38%lines of our Institutions and informed consent was ob-
Hypercholesterolemia
tained from each participant. All studies were performed (serum cholesterol 5.2 mmol/L) 30%
On treatment with erythropoietin 56%during a mid-week non-dialysis day, in the morning hours
Biochemical databetween 8 am and 1 pm. Hemoglobin g/L 10619
Plasma homocysteine lmol/L 26.9 (19.3–42.8)
Plasma fibrinogen mg/dL 384.0 (271.0–542.0)Study cohort
Serum total cholesterol mmol/L 5.351.46
One hundred and ninety-eight hemodialysis patients Serum calcium mmol/L 2.30.2
Serum phosphate mmol/L 2.00.5(110 males and 88 females) with ESRD who had been on
Serum PTH pg/mL 166 (69–374)regular dialysis treatment (RDT) for at least six months Serum CRP mg/L 7.8 (3.4–16.4)
(median duration of RDT 43 months, inter-quartile range Serum albumin g/L 425
Plasma l-Arginine lmol/L 70.6 (57.9–78.8)20 to 110 months) with an ejection fraction 35% and
Data are mean  SD, median (interquartile range), or percent frequency aswithout clinical evidence of heart failure (defined as dys-
appropriate.
pnea in addition to two of the following conditions: raised
jugular pressure, bibasilar crackles, pulmonary venous
hypertension or interstitial edema on chest x-ray requir-
Quantification of L-arginine anding hospitalization or extra ultrafiltration) [9] were con-
dimethylarginine concentrationssidered eligible for the study. These patients represented
about 70% of the whole dialysis population of the four Concentrations of l-arginine and dimethylarginines
participating dialysis units. in plasma were determined by HPLC using pre-column
Patients were being treated three times weekly with derivatization with o-phthalaldehyde (OPA) using a
previously described method after extraction of plasmastandard bicarbonate dialysis (Na 138 mmol/L, HCO3
samples on CBA solid phase extraction cartridges (Var-35 mmol/L, K 1.5 mmol/L, Ca 1.25 mmol/L, Mg 0.75
ian, Harbor City, CA, USA) [11]. The coefficients ofmmol/L) or by high flux hemodialysis using 1.1 to to
variation of this method were 5.2% within-assay and1.7 m2 dialyzers either with cuprophan or semi-synthetic
5.5% between-assay; the detection limit of the assay wasmembranes. The average Kt/V in these patients was
0.1 mol/L. The plasma concentration of ADMA in nor-1.21  0.26. Dry weight was targeted in each case to
mal subjects has a positively skewed distribution with aachieve a normotensive edema-free state. All these pa-
median value of 0.95 mol/L and the 90th percentile istients were all virtually anuric (24 hour diuresis 200
2.2 mol/L.mL). The demographic, anthropometric and biochemical
characteristics of the patients are detailed in Table 1. Blood pressure measurements
Blood pressure was estimated by averaging all pre-Laboratory measurements
dialysis arterial pressure recordings during the monthBlood sampling was performed during a mid-week
before the study (total of 12 measurements; that is,
non-dialysis day after 20 to 30 minutes of quiet resting
3/week) [12].
in semirecumbent position. Samples were taken into pre-
chilled ethylenediaminetetraacetic acid (EDTA) vacu- Echocardiography
tainers, placed immediately on ice, centrifuged within 30 These studies were performed during a mid-week non-
minutes at 4C and the plasma stored at 80C until dialysis day, within two hours after blood sampling. Left
analysis. ventricular mass (LVM) was calculated according to the
Serum lipids, albumin, calcium, phosphate and hemo- Devereux cube formula and indexed to height2.7 (LVMI)
globin measurements were made using standard methods [13]. LVH was defined by a LVMI of over 47 g/m2.7 in
in the routine clinical laboratory. C-reactive protein women or over 50 g/m2.7 in men [13]. The height-based
(CRP) levels were measured by a commercially available indexing of LVM was specifically chosen to minimize any
kit (Behring, Scoppito, L’Aquila, Italy). Plasma homo- potential distortion attributable to extracellular volume
cysteine was quantified by a high-pressure liquid chroma- expansion (surface area indexing being weight-sensi-
tive). The relative wall thickness [RWT; 2*posteriortography (HPLC) method [10].
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Table 2. Echocardiographic parameters of heart geometry andwall thickness/left ventricular end diastolic diameter
function in the study population
(LVEDD)] was also calculated as an index of the left
Left ventricular end diastolic diameter cm 5.040.67ventricular geometric pattern. Values indicative of con-
Posterior wall thickness cm 1.100.20
centric and eccentric left ventricular geometry were es- Inter-ventricular septum cm 1.170.20
Mean wall thickness cm 1.130.19tablished on the basis of age-specific reference standards
Relative wall thickness 0.450.11[14]. Systolic dysfunction was defined as a LV ejection
Left ventricular mass index g/m2.7 60.918.4
fraction 45%. Mean wall thickness (MWT) was calcu- Ejection fraction % 58.79.9
lated by the standard formula [(inter-ventricular septum Data are expressed as mean  SD.
thickness 	 posterior wall thickness)]/2.
Statistical analyses
90th percentile of the normal range (2.2 mol/L) inData are reported as mean  SD or as median and
the majority of dialysis patients (118 of 198; 60%).inter-quartile range, as appropriate. Variables that did
One hundred forty-seven patients displayed LVH onnot show a Gaussian distribution (Kolmogorov-Smirnov
echocardiography (eccentric LVH, N 75, 38%; concen-test) were log transformed before further analyses
tric LVH, N  72, 36%; normal LVM, N  51, 26%).(log10). Relationships between paired parameters were Systolic dysfunction was present in 22 patients (11%).analyzed by the least squares method.
Echocardiographic parameters of heart geometry are de-To perform multiple linear regression analysis of
tailed in Table 2.LVMI, MWT and RWT, a set of independent variables
were identified including plasma ADMA as well as a Left ventricular hypertrophy, systolic dysfunction,
series of traditional and non-traditional cardiovascular and plasma ADMA
risk factors in dialysis patients [age, sex, diabetes, previ- Plasma ADMA was significantly higher (P 0.008) in
ous cardiovascular events, duration of RDT, number of patients with LVH (median 3.00 mol/L, inter-quartile
antihypertensive drugs, smoking, systolic pressure, cho- range 1.73 to 3.97 mol/L) than in those without this
lesterol, fibrinogen, homocysteine, parathyroid hormone alteration (1.88 mol/L, 1.15 to 3.56 mol/L). Similarly,
(PTH), calcium, phosphate, CRP, albumin, hemoglobin plasma ADMA was significantly higher (P  0.02) in
and Kt/V]. To test the independent relationship between patients with systolic dysfunction (3.52 mol/L, 2.08 to
plasma ADMA and left ventricular ejection fraction we 5.87 mol/L) than in those with normal left ventricular
constructed a multivariate model based on age, heart function (2.58 mol/L, 1.53 to 3.84 mol/L).
rate, diastolic pressure and left ventricular end diastolic
volume. Independent variables were selected by a step- Univariate and multivariate analysis of
wise approach. Significant independent variables were echocardiographic parameters
ordered according to their standardized effect, defined On univariate analysis plasma ADMA was directly
as regression coefficient/standard error of the regression. related to MWT, RWT and LVMI (Fig. 1 A–C), and
By this approach we constructed models of adequate inversely related to ejection fraction (Fig. 1D). There
statistical power (at least 28 subjects for each variable was also a tendency for ADMA to be inversely related
in the final model). with LVEDD but this correlation was of marginal statis-
The link between plasma ADMA and concentric LVH tical significance (r0.12, P 0.098). On multivariate
was tested by analysis of variance (ANOVA) and by the analysis plasma ADMA was confirmed to be an indepen-
analysis of receiver operating characteristic (ROC) curve dent correlate of LVMI as well as of the muscular compo-
[15]. The diagnostic threshold of plasma ADMA for the nent (MWT and RWT) of the left ventricle (Table 3).
identification of concentric LVH in dialysis patients was Similarly, multivariate analysis confirmed that plasma
defined as the ADMA value combining better sensitivity ADMA was an independent correlate of left ventricular
and specificity, that is, as the optimal value in the ROC ejection fraction (  0.24, P  0.001) in a model
curve and the confidence intervals of sensitivity, specific- including left ventricular end diastolic volume ( 
0.46, P  0.001) and heart rate ( 0.24, P  0.001;ity, positive and negative prediction values were calcu-
multiple R  0.56, P  0.001). In this model age (P lated by a standard formula [16]. All calculations were
0.06) and diastolic pressure (P  0.17) failed to be sig-done using a standard statistical package (SPSS for Win-
nificantly related to left ventricular ejection fraction.dows Version 9.0.1, 11 Mar 1999; SPSS Inc., Chicago,
IL, USA).
Discriminant power of plasma ADMA for the
identification of concentric LVH
RESULTS Patients with concentric LVH had markedly increased
Plasma ADMA concentration (median 2.61 mol/L, plasma ADMA in comparison to patients with eccentric
LVH or normal LV mass (Fig. 2).inter-quartile range 1.58-3.96 mol/L) was above the
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Fig. 1. Relationships between plasma asymmetric dimethylarginine (ADMA) and mean wall thickness (MWT; A), relative wall thickness (RWT;
B), left ventricular mass index (LVMI; C ) and left ventricular ejection fraction (D).
Notably, plasma ADMA showed a potential diagnos- Nitric oxide generation and endothelium-dependent
tic value for the identification of concentric LVH because vasodilation in ESRD
the area under the corresponding ROC curve (Fig. 3) Total body NO production, either estimated from
was significantly (P  0.001) greater than the threshold 15N-citrulline accumulation [17] or by whole body NO
of diagnostic indifference (50%). When data were ana- balance [18] is reduced in patients with moderate to
lyzed on the basis of the “best cut-off” derived from the severe renal failure. Whether the NO synthesis rate is
ROC curve (2.76 mol/L), the sensitivity was 79% (95% reduced in patients with ESRD is still unclear, because
CI, 70 to 88%) and the specificity was 70% (95% CI, 62 a recent study reported an increased whole body NO
to 78%). The positive predictive value was 60% (95% synthesis in these patients, but this increase appeared
CI, 50 to 70%) while the negative predictive value was
largely independent of dialysis treatment [19]. At least85% (95% CI, 78 to 92%).
four studies have documented impaired endothelial va-
sodilatory responses to ischemia [8, 20] or acetylcholine
DISCUSSION [21, 22] in hemodialysis patients or in normotensive chil-
dren with chronic renal disease. Thus, although it re-In a large group of hemodialysis patients the endoge-
mains still to be established whether whole body NOnous inhibitor of nitric oxide synthase (NOS), ADMA,
generation is reduced in ESRD, it is unquestionable thatwas strongly associated to LVM, particularly to concen-
tric LVH, and was inversely related to LV function. renal failure has a direct adverse effect on endothelial
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Table 3. Multiple regression models of LVMI, MWT and RWT
 P
Dependent variable: LVMIa multiple R  0.57, P  0.001
Independent variable
Systolic pressure 0.27 0.001
Serum albumin 0.25 0.001
Previous cardiovascular events 0.22 0.001
Plasma ADMA 0.17 0.006
Male sex 0.14 0.02
Age 0.13 0.05
Dependent variable: MWTb multiple R  0.61, P  0.001
Independent variable
Systolic pressure 0.27 0.001
Serum albumin 0.26 0.001
Plasma ADMA 0.25 0.001 Fig. 2. Relationship between plasma ADMA and geometric pattern
Smoking 0.19 0.002 of the left ventricle. Data are median and inter-quartile range. *P 
Plasma fibrinogen 0.18 0.004 0.001 vs. patients with eccentric hypertrophy or with normal LVM.
Hemoglobin 0.15 0.01
Dependent variable: RWTc multiple R  0.54, P  0.001
Independent variable
Serum albumin 0.22 0.002
Plasma ADMA 0.19 0.005
Plasma fibrinogen 0.18 0.008
Duration of RDT 0.17 0.01
Systolic pressure 0.17 0.01
Serum cholesterol 0.14 0.04
Hemoglobin 0.13 0.04
Data are expressed as standardized regression coefficients () and P values.
a Out of the model: PTH (0.07), hemoglobin (P  0.11), number of antihyper-
tensive drugs (P  0.11), smoking (P  0.21), phosphate (P  0.23), diabetes
(P  0.25), fibrinogen (P  0.38), Kt/V (P  0.46), duration of RDT (P  0.71),
homocysteine (P  0.92), CRP (P  0.92), calcium (P  0.94), and cholesterol
(P  0.97)
b Out of the model: diabetes (P  0.11), age (P  0.19), cholesterol (P 
0.20), previous cardiovascular events (P  0.25), number of antihypertensive
drugs (P  0.29), Kt/V (P  0.31), duration of RDT (P  0.31), calcium (P 
0.43), phosphate (P  0.46), male sex (P  0.63), CRP (P  0.78), PTH (P 
0.92), and homocysteine (P  0.97)
c Out of the model: smoking (P  0.28), homocysteine (P  0.36), diabetes
(P  0.39), male sex (P  0.43), PTH (P  0.46), CRP (P  0.60), Kt/V (P 
0.63), number of antihypertensive drugs (P  0.63), age (P  0.74), previous
cardiovascular events (P  0.82), phosphate (P  0.97), and calcium (P  0.97)
function and that this effect most likely depends on de-
Fig. 3. Receiver operating characteristic (ROC) curves for plasmafective NO generation or bioavailability. This may influ- ADMA concentration in predicting concentric left ventricular hypertro-
ence later morbidity and mortality from large vessel ath- phy (see Methods section; area, 0.73; 95% CI, 0.66 to 0.80; P  0.001).
erosclerotic disease and LV hypertrophy.
ADMA in ESRD
cations, and that it predicts incident cardiovascular
After the article by Vallance et al [23] plasma ADMA events in these patients.
was measured in at least 14 studies in patients with ESRD
[4, 25–36] and always found to be elevated as compared ADMA and left ventricular mass and function in
to healthy subjects. It has been argued that it is unlikely renal failure
that ADMA exerts meaningful biological effects at the Uremic patients are a population at very high cardio-
plasma concentration measured in vivo in humans [32]. vascular risk. LVH represents a main component of such
Although there is no conclusive proof that ADMA inter- a high risk [2]. The link between endothelial function and
feres with the cardiovascular system in uremic patients vascular hypertrophy is well demonstrated in hyperten-
in vivo, most hemodynamic studies performed so far are sive humans [37]. Interestingly, in patients with essential
compatible with the hypothesis that NOS inhibition is in- hypertension LV mass is inversely related to forearm
volved in the endothelial dysfunction of dialysis patients blood flow response to the endothelium–dependent va-
[8, 18–21]. Furthermore, cross-sectional [4] and prospec- sodilating agent acetylcholine, and the endothelial dys-
tive studies [5] have shown that plasma ADMA concen- function in these patients is particularly pronounced in
hypertensives with concentric hypertrophy. The heart andtration is strongly associated with atherosclerotic compli-
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the arterial system form an integrated unit that coher- nosis [43]. Intervention studies are needed to see whether
the link between ADMA and concentric LVH remodel-ently responds to hemodynamic stimuli and the endothe-
lium plays a pivotal role in regulating cardiovascular ing and LV dysfunction is a causal one.
remodeling. London et al demonstrated that cardiac and
Reprint requests to Prof. Carmine Zoccali, Divisione di Nefrologia
arterial remodeling proceed in parallel in uremic patients e CNR Centro di Fisiologia Clinica, Via Sbarre Inferiori 39, 89131
Reggio Calabria, Italy.[38], and we recently confirmed these findings [39]. The
E-mail: carmine.zoccali@tin.itrelationship between endothelial dysfunction and cardio-
vascular remodeling in ESRD has been tested only in one
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